AI Article Synopsis
- Cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD) are linked to metabolic syndrome, with CVD being the leading cause of death in the West and NAFLD as the most prevalent liver condition.
- Research indicates that polyunsaturated fatty acids (PUFAs), particularly n-3 and n-6 types, play significant roles in influencing risk factors like cholesterol levels and inflammation related to CVD and NAFLD.
- The review highlights the positive impact of n-3 PUFAs, especially noting differences between plant-based alpha-linolenic acid and marine-sourced eicosapentaenoic and docosahexaenoic acids, while
Article Abstract
Cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD) are manifestations of the metabolic syndrome. CVD remains the number one cause of mortality in the West, while NAFLD is the most common liver disease. Growing evidence suggests that polyunsaturated fatty acids (PUFA) influence risk factors including circulating lipids and inflammation on the development of CVD and NAFLD. N - 6 and n - 3 PUFA are comprised of distinct family members, which are increasingly recognized for their individual effects. Therefore, this review examines what is currently known about the specific effects of the major n - 3 and n - 6 PUFA on CVD and NAFLD. Overall, this review supports a beneficial effect of n - 3 PUFA and highlights distinctive effects between alpha-linolenic acid found in plant oils relative to marine derived eicosapentaenoic acid and docosahexaenoic acid. This review also highlights contrasting health effects between the n - 6 PUFA, linoleic and arachidonic acid.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/c3fo60551e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!